Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

Hwang, Eu Chang; Gandhi, Shreyas; Jung, Jae Hung; Imamura, Mari; Kim, Myung Ha; Pang, Ruoming; Dahm, Philipp

doi:10.1002/14651858.cd007360.pub3

Cited by 10 publications

(10 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4). Se trata de un cuestionario abreviado del IIFE (29) . Consta de 5 preguntas en las que se valoran distintos aspectos de la erección, se puntúa cada respuesta de 0 a 5.…”

Section: (Nivel De Evidencia: Muy Bajo; Grado De Recomendación: Débilunclassified

“…Esta mejoría específica sobre la nocturia no se ha demostrado hasta el momento con la tamsulosina (28) . El naftopidil parece tener efectos similares en las puntuaciones de los STUI y la Cdv en comparación con la tamsulosina y la silodosina (29) . Frente a los 5-ARI, la efectividad clínica a largo plazo es mayor ante volúmenes prostáticos < 40 ml en todos los grupos de edad (4,6,17) .…”

Section: Bloqueantes De Los Receptores Alfa-1-adrenérgicos (Ab)unclassified

“…La disfunción eyaculatoria es significativamente más común con los AB que con el placebo y es probablemente mayor con silodosina que con el resto de AB (tamsulosina, naftopidil y alfuzosina) (Nivel de evidencia: alto) (40)(41)(42) . El naftopidil causa eventos adversos sexuales similares a la tamsulosina, pero menos que con la silodosina (29) . Doxazosina y terazosina se relacionan con un bajo riesgo de disfunción eyaculatoria.…”

Section: Bloqueantes De Los Receptores Alfa-1-adrenérgicos (Ab)unclassified

See 2 more Smart Citations

Untitled

2019

Med Gen Fam

View full text Add to dashboard Cite

show abstract

“…4). Se trata de un cuestionario abreviado del IIFE (29) . Consta de 5 preguntas en las que se valoran distintos aspectos de la erección, se puntúa cada respuesta de 0 a 5.…”

Section: (Nivel De Evidencia: Muy Bajo; Grado De Recomendación: Débilunclassified

Section: Bloqueantes De Los Receptores Alfa-1-adrenérgicos (Ab)unclassified

See 1 more Smart Citation

Untitled

2019

Med Gen Fam

View full text Add to dashboard Cite

show abstract

“…Alpha-adrenoreceptor blockers play a major role in managing the obstructive symptoms of BPH and are considered the first-line treatment for moderate to severe LUTS [ 3 4 ]. In addition, various alpha-adrenoreceptor blockers have been reported to be effective at improving obstructive and storage symptoms [ 5 6 ]. However, irritating storage symptoms, which may be related to consistent detrusor overactivity or which may occur secondary to bladder outlet obstruction, may persist in some BPH patients [ 1 2 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study

et al. 2020

View full text Add to dashboard Cite

Purpose To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of greater than 3 points, were initially enrolled. One group added any alpha-adrenoreceptor blocker with mirabegron 50 mg (n=39; the mirabegron group) and the other group received alpha-adrenoreceptor blocker only (n=19; the control group) for 8 weeks. Results In the control group, mean total IPSS decreased from 15.7 to 13.1 (p=0.298) and in mirabegron group, mean total IPSS decreased from 19.4 to 16.5 (p=0.024). Mean storage symptom scores reduced in the control and mirabegron groups from 8.5 to 7.9 (p=0.584) and from 9.1 to 7.6 (p=0.015), respectively, and mean QoL scores from 3.7 to 3.1 (p=0.052) and 3.6 to 3.2 (p=0.027), respectively. Mean overall OABSS in the control and mirabegron groups reduced from 8.4 to 7.2 (p=0.173) and from 8.8 to 7.3, respectively (p=0.005); mean OABSS Q3 from 3.6 to 2.9 (p=0.073) and from 3.5 to 2.7 (p=0.002), respectively; and mean OABSS Q4 from 2.4 to 2.0 (p=0.306) and from 2.7 to 2.0 (p=0.016), respectively. The change of mean Qmax and PVR was insignificant in 2 groups. Conclusions IPSS total scores, storage symptom scores, QoL, overall OABSS, OABSS Q3 and Q4 were more improved significantly by alpha-adrenoreceptor blocker with mirabegron 50 mg in BPH patients with persistent overactive symptoms. Mirabegron 50 mg addition is considered to patients with persistent storage symptoms after alpha-adrenoreceptor blocker.

show abstract

“…Naftopidil is reported to have a 3-fold higher affinity for α1D-AR than α1AAR, while tamsulosin and silodosin have much more affinity for α1A-AR than α1D-AR [ 7 , 8 ]. Naftopidil appears to have similar effects on urological symptom scores and quality of life (QoL) compared to tamsulosin and silodosin in patients with nonneurogenic LUTD, such as benign prostatic hyperplasia [ 9 ]. Currently marketed α-blockers, including naftopidil, are being prescribed in patients with neurogenic LUTD in several countries.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design

Sung¹,

Choo²,

Kim³

et al. 2020

Int Neurourol J

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the efficacy and safety of naftopidil compared with tamsulosin in patients with neurogenic lower urinary tract dysfunction (LUTD).Methods: This study was conducted as an 8-week, active-controlled, stratified-randomized, double-blind, double-dummy, parallel group, noninferiority, and multicenter clinical trial. After 2 weeks of screening, eligible subjects were randomly assigned to receive naftopidil (25 mg for 1 week followed by 75 mg for 7 weeks) or tamsulosin (0.2 mg for 8 weeks). Primary endpoint was a change of International Prostatic Symptom Score (IPSS) total score after 8 weeks of treatment.Results: One hundred ninety-four subjects with neurogenic LUTD were included into this trial. There were no differences between the 2 groups in baseline characteristics, including urodynamic study results, subtype of LUTD, pretreatment and concomitant medication, and causes of neurogenic bladder. The medication compliance rate was 94.0% (naftopidil, 93.6%; tamsulosin, 94.4%). There was a statistically significant decrease of IPSS total score at 8 weeks versus baseline in both the naftopidil (-5.64±0.66) and tamsulosin (-6.53±0.65) groups (P<0.0001 each). The mean difference between both groups was 0.89 (upper limit of 95% confidential interval, 2.72), which was lower than the noninferiority limit of 3 points. A subgroup analysis of neurologic lesions and sex found no mean difference of IPSS total score in each group. There was also no difference in safety profiles, including treatment emergent adverse events.Conclusions: Naftopidil was not inferior to tamsulosin as a therapeutic drug for patients with neurogenic LUTD and had a similar safety profile.

show abstract

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

Abstract: Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Cited by 10 publications

References 74 publications

Untitled

Untitled

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study

Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design

Contact Info

Product

Resources

About